Risk factors for FEV1 decline in European patients with CF: data from the European Cystic Fibrosis Society Patient Registry (ECFSPR)
- Elpis Hatziagorou1⇑,
- Steffen Fieuws2,
- Annalisa Orenti3,
- Lutz Naehrlich4,
- Uros Krivec5,
- Meir Mei-Zahav6,
- Andreas Jung7 and
- Kris De Boeck8
- on behalf of the ECFSPR COLLABORATIVE GROUP9
- 1Cystic Fibrosis Unit, Hippokration General Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece
- 2KU Leuven – University of Leuven, Interuniversity Institute for Biostatistics and Statistical Bioinformatics, Leuven, Belgium
- 3Department of Clinical Sciences and Community Health, Laboratory of Medical Statistics, Biometry and Epidemiology "G.A. Maccacaro", University of Milan, Milan, Italy
- 4Universities of Giessen and Marburg Lung Center, German Center of Lung Research, Justus-Liebig-University Giessen, Giessen, Germany
- 5Department of Paediatric Pulmonology, University Children's Hospital Ljubljana, University Medical Centre Ljubljana, Ljubljana, Slovenia
- 6Pulmonary Institute, Schneider Children's Medical Center of Israel, Petah Tikva, Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel
- 7Paediatric Pulmonology, University Children's Hospital Zurich, Zurich, Switzerland
- 8Paediatric Pulmonology, University Hospital of Leuven, Leuven, Belgium
- 9ECFSPR COLLABORATIVE GROUP is listed at the end of the manuscript
- Corresponding author: Elpis Hatziagorou (elpcon{at}otenet.gr)
Abstract
Aim To examine the trajectory of forced expiratory volume in 1 s (FEV1) using data from the European Cystic Fibrosis (CF) Society Patient Registry collected from 2008 to 2016, hence the era before highly effective modulator therapy (HEMT). We evaluated risk factors for FEV1 decline.
Methods The study population included patients with a confirmed diagnosis of CF recorded in the ECFPR (2008–2016). The evolution of FEV1% predicted with age (%FEV1), and the yearly change in %FEV1 were evaluated. Risk factors considered were CFTR mutation class, gender, age at diagnosis, neonatal screening, meconium ileus, sweat chloride concentration at diagnosis, and country's income level.
Results We used 199,604 FEV1 recordings from 38,734 patients. The fastest decline was seen during puberty and in patients diagnosed before ten years. Males had a higher %FEV1 but a higher yearly %FEV1 loss between ages 15 and 25. We showed stabilization and even improvement in %FEV1 over age in adults with a class III mutation but a steady decline in patients homozygous for F508del or with both mutations of classes I/II. A faster decline in %FEV1 was found in patients from 'low-income' countries compared to a similar %FEV1 evolution in patients from middle- and high-income countries.
Conclusions These longitudinal FEV1 data reflect the reality of CF across Europe in the era pre-HEMT and can serve as baseline for comparison with the post-HEMT era. The similar evolution in middle- and high-income countries underlines opportunities for low-income countries.
Footnotes
This manuscript has recently been accepted for publication in the ERJ Open Research. It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJOR online. Please open or download the PDF to view this article.
Conflict of interest: The authors declare no conflict of interest
This is a PDF-only article. Please click on the PDF link above to read it.
- Copyright ©The authors 2023
This version is distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 4.0. For commercial reproduction rights and permissions contact permissions{at}ersnet.org